Moleculin Biotech, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Moleculin Biotech, Inc. (MBRX) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$25.41 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-13
- Moleculin Biotech, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was -$25.41M.
- Moleculin Biotech, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-06-30 was -$17.81M.
- Moleculin Biotech, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-03-31 was -$5.90M.
- Moleculin Biotech, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2024-12-31 was -$6.63M.
- Moleculin Biotech, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$26.08M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2025-09-30 | -$25.41M 10-Q · filed 2025-11-13 | -$43.21M derived: sum of 2 quarters · filed 2026-08-13 | -$49.12M 10-Q · filed 2025-11-13 | -$55.74M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$17.81M 10-Q · filed 2026-08-13 | -$23.71M 10-Q · filed 2026-08-13 | -$30.34M derived: sum of 3 quarters · filed 2026-08-13 | -$37.35M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$5.90M 10-Q · filed 2026-05-14 | -$12.53M derived: sum of 2 quarters · filed 2026-05-14 | -$19.54M derived: sum of 3 quarters · filed 2026-05-14 | -$25.55M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$6.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$13.64M derived: sum of 2 quarters · filed 2026-03-18 | -$19.65M derived: sum of 3 quarters · filed 2026-03-18 | -$26.08M 10-K · filed 2026-03-18 |
| 2024-09-30 | -$7.01M 10-Q · filed 2025-11-13 | -$13.02M derived: sum of 2 quarters · filed 2025-11-13 | -$19.45M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | -$6.01M 10-Q · filed 2025-11-13 | -$12.44M 10-Q · filed 2025-11-13 | ||
| 2024-03-31 | -$6.43M 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |